Influence	O
of	O
wild	O
-	O
type	O
MLL	B-GP
on	O
glucocorticoid	O
sensitivity	O
and	O
response	O
to	O
DNA	O
-	O
damage	O
in	O
pediatric	O
acute	B-DS
lymphoblastic	I-DS
leukemia	I-DS

Background	O

Rearrangement	O
of	O
the	O
mixed	B-GP
-	I-GP
lineage	I-GP
leukemia	I-GP
gene	O
(	O
MLL	B-GP
)	O
is	O
found	O
in	O
80	O
%	O
of	O
infant	O
acute	B-DS
lymphoblastic	I-DS
leukemia	I-DS
(	O
ALL	B-DS
)	O
and	O
is	O
associated	O
with	O
poor	O
prognosis	O
and	O
resistance	O
to	O
glucocorticoids	O
(	O
GCs	O
).	O

We	O
have	O
recently	O
observed	O
that	O
GC	O
resistance	O
in	O
T	O
-	O
ALL	B-DS
cell	O
lines	O
is	O
associated	O
with	O
a	O
proliferative	O
metabolism	O
and	O
reduced	O
expression	O
of	O
MLL	B-GP
.	O

In	O
this	O
study	O
we	O
have	O
further	O
explored	O
the	O
relationship	O
between	O
MLL	B-GP
status	O
and	O
GC	O
sensitivity	O
.	O

Results	O

Negative	O
correlation	O
of	O
MLL	B-GP
expression	O
with	O
GC	O
resistance	O
in	O
15	O
T	O
-	O
ALL	B-DS
cell	O
lines	O
was	O
confirmed	O
by	O
quantitative	O
RT	O
-	O
PCR	O
.	O

The	O
absence	O
of	O
MLL	B-GP
-	O
rearrangements	O
suggested	O
that	O
this	O
relationship	O
represented	O
expression	O
of	O
wild	O
-	O
type	O
MLL	B-GP
.	O

Analysis	O
of	O
MLL	B-GP
expression	O
patterns	O
revealed	O
a	O
negative	O
relationship	O
with	O
cellular	O
metabolism	O
,	O
proliferation	O
and	O
anti	O
-	O
apoptotic	O
transcriptional	O
networks	O
.	O
In	O
silico	O
analysis	O
of	O
published	O
data	O
demonstrated	O
that	O
reduced	O
levels	O
of	O
MLL	B-GP
mRNA	O
are	O
associated	O
with	O
relapse	O
and	O
prednisolone	O
resistance	O
in	O
T	O
-	O
ALL	B-DS
patients	O
and	O
adverse	O
clinical	O
outcome	O
in	O
children	O
with	O
MLL	B-GP
-	O
rearranged	O
ALL	B-DS
.	O

RNAi	O
knockdown	O
of	O
MLL	B-GP
expression	O
in	O
T	O
-	O
ALL	B-DS
cell	O
lines	O
significantly	O
increased	O
resistance	O
to	O
dexamethasone	O
and	O
gamma	O
irradiation	O
indicating	O
an	O
important	O
role	O
for	O
wild	O
-	O
type	O
MLL	B-GP
in	O
the	O
control	O
of	O
cellular	O
apoptosis	O
.	O

Conclusions	O

The	O
data	O
suggests	O
that	O
reduced	O
expression	O
of	O
wild	O
-	O
type	O
MLL	B-GP
can	O
contribute	O
to	O
GC	O
resistance	O
in	O
ALL	B-DS
patients	O
both	O
with	O
and	O
without	O
MLL	B-GP
-	O
translocations	O
.	O

Background	O

Among	O
pediatric	O
subtypes	O
of	O
acute	B-DS
lymphoblastic	I-DS
leukemia	I-DS
(	O
ALL	B-DS
),	O
infants	O
and	O
those	O
with	O
T	O
-	O
lineage	O
ALL	B-DS
are	O
particularly	O
resistant	O
to	O
glucocorticoids	O
(	O
GCs	O
),	O
one	O
of	O
the	O
most	O
important	O
classes	O
of	O
drug	O
for	O
this	O
disease	O
[	O
1	O
].	O

Rearrangement	O
of	O
the	O
mixed	O
lineage	O
leukemia	O
gene	O
(	O
MLL	B-GP
)	O
gene	O
affects	O
80	O
%	O
of	O
ALL	B-DS
in	O
infants	O
and	O
is	O
associated	O
with	O
a	O
particularly	O
poor	O
prognosis	O
[	O
2	O
,	O
3	O
].	O
MLL	B-GP
is	O
located	O
at	O
11q23	O
and	O
encodes	O
a	O
histone	B-GP
methyltransferase	I-GP
that	O
through	O
its	O
regulation	O
of	O
HOX	B-GP
genes	O
is	O
essential	O
for	O
normal	O
mammalian	O
development	O
and	O
hematopoiesis	O
[	O
4	O
].	O

A	O
unique	O
feature	O
of	O
the	O
MLL	B-GP
locus	O
is	O
that	O
it	O
is	O
subject	O
to	O
an	O
extremely	O
wide	O
variety	O
of	O
rearrangements	O
,	O
including	O
translocations	O
with	O
>	O
50	O
partner	O
genes	O
on	O
various	O
chromosomes	O
,	O
as	O
well	O
as	O
deletions	O
,	O
inversions	O
,	O
internal	O
duplications	O
and	O
gene	O
amplifications	O
[	O
4	O
-	O
6	O
].	O

There	O
are	O
conflicting	O
reports	O
on	O
the	O
relative	O
GC	O
responses	O
of	O
patients	O
with	O
different	O
MLL	B-GP
translocations	O
[	O
7	O
,	O
8	O
],	O
but	O
those	O
with	O
t	O
(	O
4	O
;	O
11	O
)	O
translocations	O
appear	O
particularly	O
resistant	O
[	O
3	O
,	O
8	O
,	O
9	O
].	O

The	O
biological	O
basis	O
for	O
the	O
documented	O
GC	O
resistance	O
of	O
patients	O
with	O
MLL	B-GP
-	O
disease	O
has	O
not	O
been	O
explored	O
but	O
has	O
generally	O
been	O
assumed	O
to	O
be	O
due	O
to	O
the	O
oncogenic	O
effects	O
of	O
translocated	O
MLL	B-GP
fusion	O
proteins	O
.	O

Despite	O
the	O
clinical	O
importance	O
of	O
GCs	O
for	O
the	O
treatment	O
of	O
ALL	B-DS
,	O
detailed	O
knowledge	O
about	O
the	O
transduction	O
pathways	O
leading	O
to	O
GC	O
-	O
induced	O
apoptosis	O
in	O
lymphoid	O
tissues	O
remains	O
limited	O
[	O
10	O
].	O

Recently	O
we	O
performed	O
transcriptional	O
profiling	O
of	O
a	O
panel	O
of	O
T	O
-	O
ALL	B-DS
cell	O
lines	O
and	O
reported	O
that	O
GC	O
resistance	O
was	O
associated	O
with	O
a	O
proliferative	O
metabolism	O
[	O
11	O
].	O

We	O
also	O
observed	O
that	O
GC	O
resistance	O
profiles	O
were	O
significantly	O
correlated	O
with	O
reduced	O
expression	O
of	O
MLL	B-GP
.	O

In	O
this	O
study	O
we	O
have	O
further	O
investigated	O
the	O
relationship	O
between	O
MLL	B-GP
expression	O
and	O
GC	O
sensitivity	O
in	O
T	O
-	O
ALL	B-DS
and	O
provide	O
evidence	O
that	O
it	O
is	O
the	O
wild	O
-	O
type	O
expression	O
of	O
the	O
gene	O
,	O
rather	O
than	O
the	O
effect	O
of	O
translocations	O
,	O
that	O
appears	O
to	O
be	O
critical	O
for	O
determining	O
a	O
resistant	O
phenotype	O
.	O

This	O
novel	O
finding	O
may	O
help	O
to	O
explain	O
why	O
GC	O
-	O
resistance	O
is	O
a	O
common	O
feature	O
of	O
most	O
patients	O
with	O
MLL	B-GP
-	O
disease	O
despite	O
the	O
wide	O
variety	O
of	O
possible	O
gene	O
rearrangements	O

Methods	O

Cell	O
lines	O
and	O
drug	O
sensitivity	O
profiling	O

The	O
cell	O
line	O
panel	O
has	O
been	O
previously	O
described	O
and	O
comprised	O
nine	O
T	O
-	O
ALL	B-DS
lines	O
derived	O
in	O
our	O
own	O
laboratory	O
from	O
pediatric	O
ALL	B-DS
bone	O
marrow	O
specimens	O
(	O
PER	O
cell	O
lines	O
),	O
plus	O
six	O
additional	O
T	O
-	O
ALL	B-DS
cell	O
lines	O
obtained	O
from	O
external	O
sources	O
[	O
12	O
,	O
13	O
].	O

Cell	O
lines	O
were	O
grown	O
in	O
RPMI	O
-	O
1640	O
supplemented	O
with	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
10	O
nM	O
2	O
-	O
mercaptoethanol	O
and	O
10	O
-	O
20	O
%	O
heat	O
-	O
inactivated	O
fetal	O
calf	O
serum	O
.	O

The	O
media	O
for	O
PER	O
-	O
cell	O
lines	O
contained	O
additional	O
non	O
-	O
essential	O
amino	O
acids	O
and	O
pyruvate	O
,	O
whilst	O
300	O
units	O
/	O
ml	O
interleukin	B-GP
-	I-GP
2	I-GP
is	O
required	O
for	O
growth	O
of	O
PER	O
-	O
427	O
and	O
PER	O
-	O
487	O
.	O

The	O
sensitivity	O
of	O
the	O
T	O
-	O
ALL	B-DS
cell	O
lines	O
to	O
methylprednisolone	O
(	O
MPRED	O
)	O
and	O
dexamethasone	O
(	O
DEX	O
)	O
has	O
been	O
previously	O
published	O
[	O
12	O
]	O
and	O
was	O
measured	O
using	O
the	O
MTT	O
assay	O
with	O
drugs	O
incubated	O
over	O
four	O
days	O
.	O

The	O
IC50	O
(	O
drug	O
concentration	O
that	O
inhibits	O
cell	O
growth	O
by	O
50	O
%)	O
was	O
used	O
as	O
the	O
measure	O
of	O
drug	O
resistance	O
.	O

Gene	O
Expression	O
Profiling	O

Briefly	O
,	O
RNA	O
was	O
extracted	O
from	O
cell	O
lines	O
in	O
exponential	O
growth	O
phase	O
and	O
hybridized	O
to	O
Affymetrix	O
HG	O
-	O
U133A	O
microarrays	O
[	O
11	O
,	O
14	O
].	O

Microarray	O
data	O
were	O
normalized	O
using	O
robust	O
multi	O
-	O
array	O
analysis	O
(	O
RMA	O
)	O
and	O
all	O
passed	O
quality	O
control	O
criteria	O
for	O
noise	O
,	O
background	O
,	O
absent	O
/	O
present	O
calls	O
,	O
and	O
3	O
'/	O
5	O
'	O
signal	O
ratios	O
for	O
ACTB	B-GP
and	O
GAPDH	B-GP
.	O

To	O
interrogate	O
the	O
biological	O
pathways	O
represented	O
by	O
MLL	B-GP
expression	O
profiles	O
we	O
used	O
Gene	O
Set	O
Enrichment	O
Analysis	O
(	O
GSEA	O
)	O
[	O
15	O
].	O

The	O
median	O
value	O
of	O
the	O
five	O
MLL	B-GP
probe	O
sets	O
present	O
on	O
the	O
HG	O
-	O
U133A	O
was	O
calculated	O
for	O
each	O
cell	O
line	O
,	O
and	O
correlated	O
across	O
the	O
panel	O
against	O
all	O
other	O
probe	O
sets	O
on	O
the	O
array	O
using	O
Pearson	O
'	O
s	O
correlation	O
as	O
metric	O
(	O
GSEA	O
v2	O
.	O
0	O
,	O
May	O
2006	O
,	O
10	O
,	O
000	O
permutations	O
).	O

GSEA	O
examines	O
ranked	O
lists	O
of	O
genes	O
for	O
enrichment	O
of	O
biological	O
pathways	O
contained	O
within	O
four	O
different	O
databases	O
:	O
C1	O
(	O
genomic	O
loci	O
),	O
C2	O
(	O
curated	O
biological	O
pathways	O
),	O
C3	O
(	O
genes	O
with	O
common	O
regulatory	O
motifs	O
),	O
and	O
C4	O
(	O
computational	O
gene	O
networks	O
).	O

Since	O
not	O
all	O
genes	O
within	O
a	O
given	O
biological	O
pathway	O
are	O
expected	O
to	O
be	O
regulated	O
in	O
the	O
same	O
direction	O
,	O
rankings	O
were	O
performed	O
using	O
absolute	O
correlation	O
values	O
as	O
previously	O
described	O
[	O
11	O
].	O

Published	O
microarray	O
data	O
used	O
for	O
in	O
silico	O
analysis	O
[	O
14	O
,	O
16	O
-	O
18	O
]	O
was	O
downloaded	O
from	O
publicly	O
available	O
depositories	O
or	O
authors	O
'	O
websites	O
.	O

Real	O
-	O
time	O
quantitative	O
RT	O
-	O
PCR	O

Real	O
-	O
time	O
quantitative	O
RT	O
-	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
was	O
performed	O
on	O
total	O
RNA	O
from	O
cell	O
lines	O
in	O
accordance	O
with	O
standard	O
Applied	O
Biosystems	O
protocols	O
(	O
Foster	O
City	O
,	O
CA	O
)	O
and	O
in	O
accordance	O
with	O
our	O
published	O
methods	O
[	O
19	O
].	O

All	O
experiments	O
were	O
run	O
in	O
duplicates	O
on	O
an	O
ABI	O
7700	O
sequence	O
detector	O
and	O
data	O
normalized	O
to	O
expression	O
of	O
beta	B-GP
-	I-GP
actin	I-GP
(	O
ACTB	B-GP
).	O

Primers	O
and	O
probe	O
for	O
MLL	B-GP
and	O
GILZ	B-GP
qRT	O
-	O
PCR	O
were	O
purchased	O
from	O
Applied	O
Biosystems	O
(	O
ABI	O
Assays	O
on	O
Demand	O
);	O
the	O
MLL	B-GP
assay	O
targeted	O
exons	O
30	O
-	O
31	O
(	O
Refseq	O
NM_005933	O
).	O

RNAi	O
knockdown	O
of	O
MLL	B-GP
expression	O

Three	O
pSM2	O
retroviral	O
RNAi	O
vectors	O
for	O
MLL	B-GP
(	O
V2HS_196843	O
,	O
V2HS_198375	O
,	O
V2HS_214961	O
)	O
and	O
a	O
non	O
-	O
silencing	O
(	O
NS	O
)	O
control	O
vector	O
were	O
obtained	O
from	O
Open	O
Biosystems	O
(	O
Huntsville	O
,	O
USA	O
).	O

For	O
optimal	O
mammalian	O
expression	O
,	O
shRNA	O
inserts	O
were	O
subcloned	O
with	O
EcoRI	B-GP
and	O
XhoI	B-GP
into	O
MSCV	O
-	O
LMP	O
(	O
MSCV	O
/	O
LTRmiR30	O
-	O
PIGΔRI	O
,	O
a	O
generous	O
gift	O
from	O
Prof	O
.	O

Scott	O
Lowe	O
,	O
Cold	O
Spring	O
Harbour	O
Laboratory	O
[	O
20	O
]),	O
which	O
contains	O
GFP	B-GP
and	O
puromycin	O
selection	O
cassettes	O
and	O
drives	O
miR30	O
-	O
shRNA	O
expression	O
using	O
the	O
retroviral	O
5	O
'	O
LTR	O
.	O

V2HS_198375	O
(	O
MLL198	O
)	O
was	O
found	O
to	O
suppress	O
MLL	B-GP
expression	O
most	O
efficiently	O
in	O
transient	O
transfection	O
experiments	O
and	O
was	O
used	O
for	O
subsequent	O
experiments	O
.	O

The	O
retroviral	O
packaging	O
cell	O
line	O
PA317	O
(	O
selected	O
in	O
HAT	O
medium	O
)	O
was	O
transfected	O
with	O
linearised	O
miR30	O
-	O
shRNA	O
plasmid	O
DNA	O
(	O
for	O
both	O
NS	O
control	O
and	O
MLL198	O
)	O
using	O
Lipofectamine	O
,	O
and	O
GFP	B-GP
-	O
positive	O
cells	O
were	O
selected	O
with	O
puromycin	O
.	O

Stably	O
transfected	O
retroviral	O
-	O
producing	O
PA317	O
cell	O
lines	O
were	O
γ	O
-	O
irradiated	O
(	O
30	O
Gy	O
)	O
and	O
incubated	O
at	O
37	O
°	O
C	O
overnight	O
before	O
co	O
-	O
culture	O
with	O
PER	O
-	O
117	O
cells	O
for	O
48	O
hours	O
.	O

Retrovirally	O
infected	O
PER	O
-	O
117	O
cells	O
were	O
subsequently	O
removed	O
and	O
selected	O
with	O
puromycin	O
to	O
generate	O
cell	O
lines	O
stably	O
expressing	O
shRNA	O
for	O
MLL	B-GP
(	O
MLL	B-GP
-	O
KD	O
)	O
or	O
the	O
NS	O
control	O
(	O
MLL	B-GP
-	O
Scr	O
).	O

Efficiency	O
of	O
RNAi	O
knockdown	O
for	O
MLL	B-GP
was	O
assessed	O
both	O
by	O
qRT	O
-	O
PCR	O
as	O
described	O
above	O
,	O
and	O
by	O
immunoblot	O
of	O
nuclear	O
protein	O
extracted	O
from	O
cell	O
lines	O
in	O
log	O
-	O
phase	O
growth	O
using	O
standard	O
methods	O
.	O

Antibodies	O
used	O
were	O
mouse	B-OG
anti	O
-	O
MLLC	O
/	O
HRX	B-GP
,	O
clone	O
9	O
-	O
12	O
(	O
Upstate	O
Cell	O
Signaling	O
Solutions	O
,	O
Temecula	O
,	O
CA	O
),	O
which	O
detects	O
the	O
C	O
-	O
terminal	O
proteolytic	O
fragment	O
of	O
MLL	B-GP
(~	O
180	O
kDa	O
),	O
and	O
mouse	B-OG
anti	O
-	O
human	B-OG
β	B-GP
-	I-GP
actin	I-GP
as	O
loading	O
control	O
(	O
Pan	O
Actin	B-GP
Ab	O
-	O
5	O
(	O
ACTN05	O
)	O
NeoMarkers	O
,	O
Fremont	O
CA	O
).	O

Densitometric	O
quantitation	O
of	O
protein	O
bands	O
from	O
multiple	O
extractions	O
taken	O
at	O
independent	O
time	O
points	O
and	O
from	O
different	O
cell	O
-	O
line	O
stocks	O
was	O
performed	O
using	O
ImageJ	O
software	O
http	O
://	O
rsbweb	O
.	O
nih	O
.	O
gov	O
/	O
ij	O
/,	O
with	O
MLL	B-GP
expression	O
normalized	O
to	O
β	B-GP
-	I-GP
actin	I-GP
loading	O
.	O

Cellular	O
assays	O

Cell	O
growth	O
and	O
viability	O
were	O
measured	O
using	O
the	O
Vi	O
-	O
CELL	O
XR	O
Viable	O
Cell	O
Analyzer	O
(	O
Beckman	O
Coulter	O
).	O

Cells	O
in	O
exponential	O
growth	O
phase	O
were	O
seeded	O
at	O
5	O
×	O
105	O
ml	O
-	O
1	O
in	O
a	O
96	O
-	O
well	O
plate	O
in	O
the	O
presence	O
or	O
absence	O
of	O
dexamethasone	O
(	O
10	O
μg	O
/	O
ml	O
-	O
258	O
μg	O
/	O
ml	O
,	O
Mayne	O
Pharma	O
Pty	O
Ltd	O
,	O
VIC	O
,	O
Australia	O
),	O
0	O
.	O
025	O
μg	O
/	O
ml	O
cytarabine	O
(	O
ARAC	O
;	O
Pharmacia	O
Pty	O
Ltd	O
,	O
NSW	O
,	O
Australia	O
),	O
0	O
.	O
01	O
μg	O
/	O
ml	O
methotrexate	O
(	O
MTX	O
;	O
David	O
Bull	O
Laboratories	O
),	O
or	O
1	O
Gy	O
gamma	O
-	O
irradiation	O
,	O
and	O
incubated	O
for	O
two	O
days	O
at	O
37	O
°	O
C	O
before	O
measuring	O
cell	O
survival	O
.	O

Each	O
drug	O
concentration	O
or	O
condition	O
was	O
tested	O
in	O
triplicate	O
and	O
data	O
were	O
normalised	O
to	O
values	O
obtained	O
from	O
untreated	O
cells	O
.	O

For	O
metabolic	O
assays	O
,	O
cells	O
in	O
exponential	O
growth	O
were	O
seeded	O
at	O
5	O
×	O
105	O
ml	O
-	O
1	O
in	O
fresh	O
media	O
and	O
incubated	O
for	O
two	O
days	O
at	O
37	O
°	O
C	O
before	O
harvesting	O
supernatants	O
.	O

Glucose	O
and	O
lactate	O
supernatant	O
concentrations	O
were	O
measured	O
using	O
the	O
Amplex	O
Red	O
kit	O
(	O
Invitrogen	O
,	O
Australia	O
),	O
substituting	O
lactate	B-GP
oxidase	I-GP
(	O
Sigma	O
,	O
Australia	O
)	O
as	O
required	O
.	O

For	O
assessment	O
of	O
GILZ	B-GP
induction	O
,	O
MLL	B-GP
-	O
KD	O
and	O
MLL	B-GP
-	O
Scr	O
cells	O
in	O
exponential	O
growth	O
were	O
incubated	O
with	O
1	O
μM	O
dexamethasone	O
(	O
Mayne	O
Pharma	O
Pty	O
Ltd	O
,	O
VIC	O
,	O
Australia	O
)	O
for	O
four	O
hours	O
prior	O
to	O
RNA	O
extraction	O
and	O
measurement	O
by	O
qRT	O
-	O
PCR	O
.	O

Results	O

MLL	B-GP
mRNA	O
Expression	O
and	O
GC	O
resistance	O
in	O
T	O
-	O
ALL	B-DS
Cell	O
Lines	O

Our	O
laboratory	O
has	O
developed	O
an	O
authenticated	O
panel	O
of	O
pediatric	O
T	O
-	O
ALL	B-DS
cell	O
lines	O
that	O
have	O
been	O
grown	O
in	O
the	O
absence	O
of	O
drug	O
selection	O
.	O

These	O
cultures	O
retain	O
critical	O
features	O
of	O
the	O
primary	O
disease	O
and	O
their	O
drug	O
resistance	O
profile	O
parallels	O
the	O
spectrum	O
of	O
resistance	O
that	O
has	O
been	O
observed	O
in	O
primary	O
patient	O
specimens	O
[	O
12	O
].	O

We	O
recently	O
examined	O
the	O
baseline	O
resistance	O
of	O
these	O
15	O
T	O
-	O
ALL	B-DS
cell	O
lines	O
to	O
the	O
GCs	O
DEX	O
and	O
MPRED	O
[	O
12	O
]	O
and	O
correlated	O
the	O
data	O
with	O
gene	O
expression	O
profiles	O
as	O
determined	O
by	O
HG	O
-	O
U133A	O
microarray	O
[	O
11	O
].	O

Although	O
these	O
lines	O
have	O
been	O
cultured	O
without	O
prior	O
exposure	O
to	O
in	O
vitro	O
drug	O
selection	O
pressure	O
they	O
demonstrate	O
a	O
natural	O
spectrum	O
of	O
GC	O
resistance	O
,	O
with	O
IC50	O
values	O
across	O
the	O
panel	O
varying	O
by	O
4	O
-	O
5	O
orders	O
of	O
magnitude	O
(	O
Figure	O
1A	O
).	O

This	O
resistance	O
profile	O
is	O
not	O
explained	O
by	O
mutations	O
in	O
the	O
glucocorticoid	B-GP
receptor	I-GP
(	O
GR	B-GP
)	O
or	O
variations	O
in	O
its	O
level	O
of	O
expression	O
[	O
21	O
],	O
indicating	O
that	O
defects	O
downstream	O
of	O
the	O
GR	B-GP
are	O
primarily	O
responsible	O
for	O
GC	O
resistant	O
phenotypes	O
in	O
these	O
cell	O
lines	O
.	O

Relationship	O
between	O
MLL	B-GP
expression	O
and	O
GC	O
resistance	O
in	O
T	O
-	O
ALL	B-DS
Cell	O
Lines	O
.	O

(	O
A	O
)	O
Normalized	O
MLL	B-GP
mRNA	O
expression	O
across	O
the	O
T	O
-	O
ALL	B-DS
cell	O
line	O
panel	O
as	O
measured	O
by	O
qRT	O
-	O
PCR	O
(	O
bars	O
)	O
and	O
IC50	O
values	O
for	O
MPRED	O
(	O
open	O
circles	O
)	O
and	O
DEX	O
(	O
closed	O
squares	O
);	O
(	O
B	O
)	O
Schematic	O
of	O
MLL	B-GP
mRNA	O
indicating	O
the	O
target	O
location	O
of	O
five	O
microarray	O
probes	O
(	O
indicated	O
by	O
solid	O
lines	O
)	O
and	O
protein	O
domains	O
within	O
the	O
coding	O
region	O
:	O
MBR	O
,	O
Major	O
Break	O
Region	O
;	O
RD	O
,	O
Repression	O
Domain	O
;	O
TAD	O
,	O
Transactivation	O
Domain	O
;	O
PC	O
,	O
site	O
of	O
proteolytic	O
cleavage	O
.	O

Correlation	O
of	O
expression	O
level	O
vs	O
.	O
cell	O
line	O
IC50	O
for	O
DEX	O
(	O
D	O
)	O
and	O
MPRED	O
(	O
M	O
)	O
is	O
indicated	O
for	O
each	O
probe	O
(*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
01	O
,	O
***	O
p	O
<	O
0	O
.	O
001	O
,	O
****	O
p	O
<	O
0	O
.	O
0001	O
).	O

Our	O
analysis	O
of	O
the	O
microarray	O
data	O
revealed	O
that	O
GC	O
resistance	O
was	O
significantly	O
correlated	O
with	O
reduced	O
expression	O
of	O
MLL	B-GP
[	O
11	O
].	O

To	O
confirm	O
this	O
correlation	O
we	O
used	O
qRT	O
-	O
PCR	O
to	O
measure	O
MLL	B-GP
mRNA	O
expression	O
across	O
the	O
panel	O
,	O
using	O
a	O
probe	O
targeting	O
the	O
3	O
'	O
end	O
of	O
the	O
MLL	B-GP
coding	O
region	O
.	O

Expression	O
levels	O
measured	O
by	O
qRT	O
-	O
PCR	O
were	O
highly	O
correlated	O
with	O
resistance	O
to	O
both	O
GCs	O
(	O
Figure	O
1A	O
;	O
correlation	O
vs	O
.	O
dexamethasone	O
IC50	O
-	O
0	O
.	O
849	O
(	O
p	O
<	O
0	O
.	O
0001	O
),	O
methylprednisolone	O
IC50	O
-	O
0	O
.	O
851	O
(	O
p	O
<	O
0	O
.	O
0001	O
)).	O

Whilst	O
translocations	O
of	O
the	O
MLL	B-GP
gene	O
are	O
prevalent	O
in	O
infant	O
ALL	B-DS
they	O
are	O
infrequent	O
in	O
T	O
-	O
ALL	B-DS
[	O
8	O
,	O
9	O
,	O
22	O
],	O
suggesting	O
that	O
the	O
observed	O
correlation	O
reflected	O
expression	O
of	O
the	O
wild	O
-	O
type	O
gene	O
.	O

Indeed	O
,	O
T	O
-	O
ALL	B-DS
cell	O
line	O
karyotypes	O
indicated	O
no	O
abnormalities	O
at	O
the	O
11q23	O
MLL	B-GP
-	O
locus	O
[	O
12	O
],	O
a	O
conclusion	O
confirmed	O
by	O
Southern	O
Blot	O
for	O
all	O
15	O
cell	O
lines	O
(	O
data	O
not	O
shown	O
).	O

On	O
the	O
HG	O
-	O
U133A	O
microarray	O
there	O
are	O
five	O
independent	O
probes	O
for	O
MLL	B-GP
,	O
and	O
these	O
span	O
the	O
entire	O
length	O
of	O
the	O
gene	O
,	O
encompassing	O
both	O
sides	O
of	O
the	O
major	O
break	O
region	O
(	O
MBR	O
)	O
that	O
is	O
involved	O
in	O
almost	O
all	O
translocation	O
events	O
(	O
Figure	O
1B	O
).	O

Across	O
the	O
15	O
T	O
-	O
ALL	B-DS
cell	O
lines	O
correlation	O
of	O
MLL	B-GP
mRNA	O
expression	O
and	O
GC	O
resistance	O
was	O
significant	O
for	O
all	O
five	O
probe	O
sets	O
(	O
median	O
probe	O
significance	O
DEX	O
p	O
=	O
0	O
.	O
0025	O
,	O
MPRED	O
p	O
<	O
0	O
.	O
0001	O
)	O
indicating	O
no	O
discrepancy	O
in	O
expression	O
between	O
the	O
5	O
'	O
and	O
3	O
'	O
regions	O
of	O
the	O
gene	O
.	O

Based	O
on	O
these	O
data	O
we	O
conclude	O
that	O
the	O
observed	O
correlation	O
with	O
GC	O
sensitivity	O
in	O
T	O
-	O
ALL	B-DS
cell	O
lines	O
is	O
related	O
to	O
expression	O
levels	O
of	O
wild	O
-	O
type	O
MLL	B-GP
rather	O
than	O
MLL	B-GP
-	O
translocation	O
products	O
.	O

Biological	O
features	O
of	O
MLL	B-GP
expression	O
in	O
T	O
-	O
ALL	B-DS

To	O
gain	O
further	O
insight	O
into	O
the	O
transcriptional	O
programs	O
associated	O
with	O
MLL	B-GP
,	O
the	O
expression	O
profile	O
of	O
this	O
gene	O
across	O
the	O
T	O
-	O
ALL	B-DS
cell	O
line	O
panel	O
was	O
correlated	O
to	O
the	O
expression	O
of	O
all	O
other	O
genes	O
on	O
the	O
microarray	O
.	O

This	O
output	O
was	O
analyzed	O
with	O
GSEA	O
to	O
identify	O
the	O
biological	O
networks	O
associated	O
with	O
variations	O
in	O
MLL	B-GP
expression	O
.	O

The	O
strongest	O
signatures	O
were	O
returned	O
from	O
the	O
C2	O
(	O
curated	O
pathway	O
)	O
and	O
C4	O
(	O
computational	O
gene	O
network	O
)	O
databases	O
,	O
with	O
17	O
and	O
83	O
enriched	O
gene	O
sets	O
respectively	O
falling	O
within	O
the	O
significant	O
GSEA	O
false	O
discovery	O
rate	O
(	O
FDR	O
).	O

Very	O
few	O
significantly	O
enriched	O
gene	O
sets	O
were	O
identified	O
from	O
genomic	O
loci	O
and	O
regulatory	O
-	O
motif	O
databases	O
(	O
C1	O
and	O
C3	O
).	O

The	O
top	O
ranked	O
significant	O
gene	O
sets	O
from	O
the	O
C2	O
and	O
C4	O
databases	O
are	O
listed	O
in	O
Tables	O
1	O
&	O
2	O
.	O

The	O
majority	O
of	O
these	O
pathways	O
are	O
involved	O
with	O
the	O
control	O
of	O
cell	O
growth	O
and	O
metabolism	O
(	O
e	O
.	O
g	O
.	O
MYC	B-GP
-	O
regulated	O
pathways	O
,	O
RNA	O
transcription	O
,	O
oxidative	O
phosphorylation	O
,	O
the	O
TCA	O
cycle	O
,	O
proteasomal	O
regulation	O
,	O
nucleotide	O
synthesis	O
,	O
translation	O
initiation	O
and	O
antioxidant	O
defense	O
).	O

The	O
overwhelming	O
direction	O
of	O
expression	O
of	O
these	O
pathways	O
was	O
a	O
negative	O
correlation	O
with	O
expression	O
of	O
MLL	B-GP
.	O

Thus	O
lower	O
expression	O
of	O
MLL	B-GP
in	O
these	O
cell	O
lines	O
is	O
associated	O
with	O
signatures	O
consistent	O
with	O
a	O
proliferative	O
phenotype	O
.	O

In	O
addition	O
the	O
expression	O
levels	O
measured	O
by	O
each	O
of	O
the	O
five	O
MLL	B-GP
probe	O
sets	O
were	O
found	O
to	O
correlate	O
significantly	O
with	O
cell	O
line	O
doubling	O
times	O
[	O
12	O
]	O
(	O
median	O
correlation	O
0	O
.	O
67	O
,	O
p	O
<	O
0	O
.	O
01	O
).	O

These	O
findings	O
are	O
in	O
keeping	O
with	O
our	O
previous	O
observation	O
that	O
reduced	O
expression	O
of	O
MLL	B-GP
is	O
part	O
of	O
a	O
proliferative	O
metabolism	O
signature	O
that	O
is	O
associated	O
with	O
GC	O
resistance	O
in	O
T	O
-	O
ALL	B-DS
cell	O
lines	O
[	O
11	O
].	O

Importantly	O
,	O
several	O
gene	O
sets	O
were	O
involved	O
with	O
the	O
regulation	O
of	O
apoptosis	O
(	O
MORF_AATF	O
,	O
MORF_MAPK2	B-GP
),	O
p53	B-GP
response	O
(	O
MORF_EI24	O
,	O
GNF2_NS	O
)	O
and	O
DNA	O
damage	O
repair	O
(	O
MORF_UNG	O
),	O
with	O
the	O
direction	O
of	O
association	O
linking	O
reduced	O
MLL	B-GP
-	O
expression	O
with	O
the	O
activation	O
of	O
anti	O
-	O
apoptotic	O
transcriptional	O
networks	O
(	O
Table	O
2	O
).	O

Top	O
ranked	O
GSEA	O
gene	O
sets	O
from	O
the	O
C2	O
database	O
(	O
curated	O
pathways	O
)	O
associated	O
with	O
MLL	B-GP
expression	O
profiles	O
in	O
T	O
-	O
ALL	B-DS
cell	O
lines	O
.	O

Gene	O
Set	O

Description	O
of	O
Biological	O
Pathway	O

FDR	O
*	O

Electron_transport_chain	O

Electron	O
transport	O
chain	O

0	O
.	O
137	O


Glycolysis_gluconeogenesis	O

Glycolysis	O
and	O
gluconeogenesis	O

0	O
.	O
142	O


Peng_leucine_down	O

Down	O
-	O
regulated	O
in	O
response	O
to	O
leucine	O
starvation	O

0	O
.	O
145	O


RNA_transcription_reactome	O

RNA	O
transcription	O
reactome	O

0	O
.	O
145	O


Mitochondria	O

Mitochondrial	O
genes	O

0	O
.	O
148	O


Aminoacyl_tRNA_biosynthesis	O

Amino	O
-	O
acyl	O
tRNA	O
biosynthesis	O

0	O
.	O
151	O


Human_mitodb_6_2002	O

Mitochondrial	O
genes	O

0	O
.	O
152	O


Hdaci_colon_cur24hrs_up	O

Genes	O
upregulated	O
by	O
curcumin	O
,	O
transcription	O
inhibitor	O

0	O
.	O
156	O


Hdaci_colon_cur48hrs_up	O

Genes	O
upregulated	O
by	O
curcumin	O
,	O
transcription	O
inhibitor	O

0	O
.	O
163	O


Myc_huvec_sage_array_up	O

Genes	O
up	O
-	O
regulated	O
by	O
myc	B-GP

0	O
.	O
176	O


Peng_rapamycin_down	O

Down	O
-	O
regulated	O
in	O
response	O
to	O
rapamycin	O

0	O
.	O
183	O


Oxidative_phosphorylation	O

Oxidative	O
phosphorylation	O

0	O
.	O
190	O


tRNA_synthetases	O

tRNA	O
synthetases	O

0	O
.	O
192	O


Proteasome_pathway	O

Proteasomal	O
pathway	O
genes	O

0	O
.	O
200	O


Peng_glutamine_down	O

Down	O
-	O
regulated	O
in	O
response	O
to	O
glutamine	O
starvation	O

0	O
.	O
203	O


Krebs_TCA_cycle	O

Krebs	O
(	O
TCA	O
)	O
cycle	O
genes	O

0	O
.	O
204	O


Proteasome	O

Proteasome	O
genes	O

0	O
.	O
238	O

*	O
FDR	O
,	O
false	O
discovery	O
rate	O
;	O
GSEA	O
cutoff	O
for	O
significance	O
FDR	O
<	O
0	O
.	O
25	O

Top	O
ranked	O
GSEA	O
gene	O
sets	O
from	O
the	O
C4	O
database	O
(	O
computed	O
gene	O
networks	O
)	O
associated	O
with	O
MLL	B-GP
expression	O
profiles	O
in	O
T	O
-	O
ALL	B-DS
cell	O
lines	O
.	O

Gene	O
Set	O

Description	O
of	O
Network	O
Hub	O
Genes	O
and	O
Associated	O
Functions	O

FDR	O
*	O

MORF_PRDX3	B-GP

Peroxiredoxin	B-GP
3	I-GP
-	O
MYC	B-GP
-	O
mediated	O
proliferation	O
,	O
glucose	O
responses	O

0	O
.	O
132	O


MORF_SOD1	B-GP

Superoxide	B-GP
dismutase	I-GP
1	I-GP
-	O
mitochondria	O
,	O
oxidative	O
metabolism	O

0	O
.	O
135	O


MORF_MAP2K2	O

MAP2K2	B-GP
-	O
ERK	B-GP
,	O
JNK	B-GP
,	O
p38	B-GP
,	O
NFkB	B-GP
,	O
and	O
apoptosis	O
pathways	O

0	O
.	O
138	O


MORF_PTPN11	B-GP

Protein	B-GP
tyrosine	I-GP
phosphatase	I-GP
,	O
cell	O
growth	O
,	O
differentiation	O
,	O
metabolism	O

0	O
.	O
140	O


GNF2_RAN	O

RAS	B-GP
oncogene	I-GP
family	I-GP
-	O
cell	O
cycle	O
,	O
mitotic	O
spindle	O
regulation	O

0	O
.	O
143	O


MORF_GMPS	O

Guanine	B-GP
monphosphate	I-GP
synthetase	I-GP
-	O
purine	O
synthesis	O
,	O
cell	O
cycle	O

0	O
.	O
146	O


MORF_DEAF1	O

DEAF1	B-GP
or	O
supressin	O
,	O
inhibitor	O
of	O
proliferation	O

0	O
.	O
152	O


MORF_ERH	B-GP

Enhancer	B-GP
of	I-GP
rudimentary	I-GP
homolog	I-GP
-	O
cell	O
cycle	O
regulator	O

0	O
.	O
155	O


GNF2_NS	O

Nucleostemin	B-GP
-	O
cell	O
cycle	O
progression	O
in	O
stem	O
cells	O
,	O
links	O
with	O
p53	B-GP

0	O
.	O
158	O


MORF_GPX4	B-GP

Glutathione	B-GP
peroxidase	I-GP
4	I-GP
-	O
cellular	O
antioxidant	O
defence	O

0	O
.	O
159	O


MORF_AATF	O

Apoptosis	O
antagonizing	O
transcription	O
factor	O

0	O
.	O
160	O


MORF_EIF3S2	O

EIF3S2	B-GP
-	O
eukaryotic	B-GP
translation	I-GP
initiation	I-GP
factor	I-GP

0	O
.	O
164	O


MORF_ATOX1	B-GP

ATX1	B-GP
antioxidant	I-GP
protein	I-GP
1	I-GP
homolog	O
-	O
antioxidant	O
defense	O

0	O
.	O
165	O


MORF_EI24	O

Etoposide	O
induced	O
mRNA	O
-	O
early	O
p53	B-GP
response	O
gene	O

0	O
.	O
166	O


MORF_PSMC1	B-GP

Proteasome	O
26S	O
subunit	O
,	O
ATPase	O

0	O
.	O
173	O


MORF_RAN	O

RAS	B-GP
oncogene	I-GP
family	I-GP
-	O
cell	O
cycle	O
,	O
mitotic	O
spindle	O
regulation	O

0	O
.	O
179	O


MORF_RAB5A	B-GP

Ras	B-GP
-	I-GP
associated	I-GP
protein	I-GP
-	O
exocytosis	O
,	O
actin	B-GP
organisation	O

0	O
.	O
180	O


MORF_UNG	O

Uracil	B-GP
-	I-GP
DNA	I-GP
glycosylase	I-GP
-	O
base	O
-	O
excision	O
DNA	O
repair	O
pathway	O

0	O
.	O
182	O


MORF_FBL	B-GP

Fibrillarin	B-GP
-	O
component	O
of	O
snRNP	O
synthesis	O
of	O
ribosomal	O
RNA	O

0	O
.	O
203	O


GCM_MAX	B-GP

Myc	B-GP
-	I-GP
associated	I-GP
factor	I-GP
X	I-GP
-	O
transcriptional	O
regulator	O

0	O
.	O
224	O

*	O
FDR	O
,	O
false	O
discovery	O
rate	O
;	O
GSEA	O
cutoff	O
for	O
significance	O
FDR	O
<	O
0	O
.	O
25	O

MLL	B-GP
-	O
Translocation	O
Partner	O
Genes	O
Correlate	O
with	O
MLL	B-GP
Expression	O

Recent	O
evidence	O
suggests	O
that	O
the	O
genes	O
most	O
commonly	O
translocated	O
with	O
MLL	B-GP
are	O
not	O
selected	O
at	O
random	O
but	O
may	O
in	O
fact	O
be	O
functionally	O
related	O
as	O
part	O
of	O
an	O
'	O
MLL	B-GP
-	O
web	O
'	O
[	O
5	O
,	O
23	O
,	O
24	O
].	O

If	O
this	O
is	O
true	O
,	O
then	O
in	O
the	O
context	O
of	O
the	O
observed	O
relationship	O
between	O
MLL	B-GP
expression	O
and	O
GC	O
resistance	O
in	O
the	O
present	O
study	O
(	O
Figure	O
1A	O
)	O
one	O
might	O
predict	O
that	O
the	O
expression	O
of	O
these	O
genes	O
would	O
similarly	O
be	O
correlated	O
with	O
GC	O
resistance	O
in	O
our	O
T	O
-	O
ALL	B-DS
cell	O
lines	O
.	O

Of	O
the	O
>	O
50	O
known	O
translocation	O
partner	O
genes	O
of	O
MLL	B-GP
,	O
43	O
are	O
represented	O
on	O
the	O
HG	O
-	O
U133A	O
microarray	O
(	O
corresponding	O
to	O
a	O
total	O
of	O
93	O
probe	O
sets	O
).	O

Despite	O
the	O
absence	O
of	O
MLL	B-GP
-	O
translocations	O
in	O
the	O
T	O
-	O
ALL	B-DS
cell	O
lines	O
we	O
observed	O
that	O
a	O
large	O
number	O
of	O
these	O
(	O
18	O
genes	O
,	O
26	O
probe	O
sets	O
)	O
were	O
significantly	O
correlated	O
to	O
MPRED	O
and	O
DEX	O
resistance	O
(	O
Table	O
3	O
).	O

This	O
association	O
is	O
much	O
greater	O
than	O
would	O
be	O
predicted	O
by	O
chance	O
alone	O
(	O
exact	O
binomial	O
test	O
,	O
p	O
<	O
0	O
.	O
001	O
).	O

It	O
is	O
relevant	O
that	O
the	O
majority	O
of	O
the	O
genes	O
listed	O
in	O
Table	O
3	O
are	O
involved	O
in	O
transcriptional	O
regulation	O
(	O
GMPS	B-GP
,	O
DCPS	B-GP
,	O
ELL	B-GP
,	O
LPP	B-GP
,	O
AF10	B-GP
,	O
CREBBP	B-GP
,	O
EP300	B-GP
,	O
AF4	B-GP
),	O
proliferation	O
(	O
GAS7	B-GP
)	O
or	O
metabolism	O
(	O
CBL	B-GP
,	O
GPHN	B-GP
and	O
ACACA	B-GP
,	O
the	O
latter	O
being	O
the	O
rate	O
limiting	O
enzyme	O
for	O
conversion	O
of	O
acetyl	O
-	O
coA	O
into	O
cholesterol	O
).	O

The	O
correlation	O
of	O
these	O
genes	O
with	O
GC	O
resistance	O
may	O
therefore	O
be	O
reflective	O
of	O
the	O
metabolic	O
and	O
proliferative	O
changes	O
driving	O
this	O
phenotype	O
in	O
T	O
-	O
ALL	B-DS
cell	O
lines	O
of	O
which	O
MLL	B-GP
appears	O
to	O
be	O
a	O
part	O
[	O
11	O
].	O

MLL	B-GP
Translocation	O
Partner	O
Genes	O
Significantly	O
Correlated	O
with	O
GC	O
IC50	O
in	O
T	O
-	O
ALL	B-DS
Cell	O
Lines	O
.	O

Probe	O
Set	O

Gene	O
Title	O

Symbol	O

Chr	O

MPRED	O

DEX	O
*	O

220773_s_at	O

Gephyrin	B-GP

GPHN	B-GP

14q23	O
.	O
3	O

0	O
.	O
915	O

0	O
.	O
670	O

212186_at	O

Acetyl	B-GP
-	I-GP
CoA	I-GP
carboxylase	I-GP
alpha	I-GP

ACACA	B-GP

17q21	O

0	O
.	O
767	O

0	O
.	O
558	O

214431_at	O

Guanine	B-GP
monphosphate	I-GP
synthetase	I-GP

GMPS	B-GP

3q24	O

0	O
.	O
754	O

0	O
.	O
505	O

218774_at	O

Decapping	O
enzyme	O
,	O
scavenger	O

DCPS	B-GP

11q24	O
.	O
2	O

0	O
.	O
637	O

0	O
.	O
744	O

204096_s_at	O

Elongation	O
factor	O
RNA	O
pol	O
II	O

ELL	B-GP

19p13	O
.	O
1	O

0	O
.	O
581	O

0	O
.	O
779	O

202821_s_at	O

LIM	O
domain	O
containing	O
preferred	O
translocation	O
partner	O
in	O
lipoma	O

LPP	B-GP

3q28	O

0	O
.	O
577	O

0	O
.	O
418	O

214358_at	O

Acetyl	B-GP
-	I-GP
CoA	I-GP
carboxylase	I-GP
alpha	I-GP

ACACA	B-GP

17q21	O

0	O
.	O
569	O

0	O
.	O
197	O

216506_x_at	O

MLL	B-GP
(	I-GP
trithorax	I-GP
homolog	I-GP
,	I-GP
Drosophila	I-GP
);	I-GP
translocated	I-GP
to	I-GP
,	I-GP
10	I-GP

MLLT10	B-GP
/	O
AF10	B-GP

10p12	O

0	O
.	O
560	O

0	O
.	O
293	O

200713_s_at	O

Microtubule	O
-	O
associated	O
protein	O
,	O
RP	O
/	O
EB	O
family	O
,	O
member	O
1	O

MAPRE1	B-GP

20q11	O
.	O
1	O
-	O
11	O
.	O
23	O

0	O
.	O
560	O

0	O
.	O
542	O

211808_s_at	O

CREB	B-GP
binding	I-GP
protein	I-GP
(	O
Rubinstein	B-DS
-	I-DS
Taybi	I-DS
syndrome	I-DS
)	O

CREBBP	B-GP

16p13	O
.	O
3	O

0	O
.	O
558	O

0	O
.	O
470	O

215578_at	O

Gephyrin	B-GP

GPHN	B-GP

14q23	O
.	O
3	O

0	O
.	O
526	O

0	O
.	O
473	O

209768_s_at	O

SEPT5	O

SEPT5	O
/	O
PNUTL	O

22q11	O
.	O
21	O

0	O
.	O
519	O

0	O
.	O
229	O

216503_s_at	O

MLL	B-GP
(	I-GP
trithorax	I-GP
homolog	I-GP
,	I-GP
Drosophila	I-GP
);	I-GP
translocated	I-GP
to	I-GP
,	I-GP
10	I-GP

MLLT10	B-GP
/	O
AF10	B-GP

10p12	O

0	O
.	O
516	O

0	O
.	O
307	O


211067_s_at	O

Growth	B-GP
arrest	I-GP
-	I-GP
specific	I-GP
7	I-GP

GAS7	B-GP

17p13	O
.	O
1	O

-	O
0	O
.	O
300	O

-	O
0	O
.	O
541	O

210872_x_at	O

Growth	B-GP
arrest	I-GP
-	I-GP
specific	I-GP
7	I-GP

GAS7	B-GP

17p13	O
.	O
1	O

-	O
0	O
.	O
334	O

-	O
0	O
.	O
580	O

202191_s_at	O

Growth	B-GP
arrest	I-GP
-	I-GP
specific	I-GP
7	I-GP

GAS7	B-GP

17p13	O
.	O
1	O

-	O
0	O
.	O
385	O

-	O
0	O
.	O
624	O

202192_s_at	O

Growth	B-GP
arrest	I-GP
-	I-GP
specific	I-GP
7	I-GP

GAS7	B-GP

17p13	O
.	O
1	O

-	O
0	O
.	O
417	O

-	O
0	O
.	O
589	O

202221_s_at	O

E1A	B-GP
binding	I-GP
protein	I-GP
p300	I-GP

EP300	B-GP

22q13	O
.	O
2	O

-	O
0	O
.	O
542	O

-	O
0	O
.	O
315	O

212288_at	O

Formin	O
binding	O
protein	O
1	O

FNBP1	B-GP

9q34	O

-	O
0	O
.	O
575	O

-	O
0	O
.	O
624	O

209027_s_at	O

Abl	B-GP
-	I-GP
interactor	I-GP
1	I-GP

ABI1	B-GP

10p11	O
.	O
2	O

-	O
0	O
.	O
580	O

-	O
0	O
.	O
417	O

205068_s_at	O

Rho	O
GTPase	O
activating	O
protein	O
26	O

ARHGAP26	B-GP

5q31	O

-	O
0	O
.	O
607	O

-	O
0	O
.	O
661	O

209028_s_at	O

Abl	B-GP
-	I-GP
interactor	I-GP
1	I-GP

ABI1	B-GP

10p11	O
.	O
2	O

-	O
0	O
.	O
608	O

-	O
0	O
.	O
472	O

214298_x_at	O

Septin	O
6	O

SEPT6	O

Xq24	O

-	O
0	O
.	O
615	O

-	O
0	O
.	O
386	O

201924_at	O

MLLT2	B-GP

MLLT2	B-GP
/	O
AF4	B-GP

4q21	O

-	O
0	O
.	O
660	O

-	O
0	O
.	O
671	O

206607_at	O

Cas	O
-	O
Br	O
-	O
M	O
(	O
murine	O
)	O
ecotropic	O
retroviral	O
transforming	O
sequence	O

CBL	B-GP

11q23	O
.	O
3	O

-	O
0	O
.	O
681	O

-	O
0	O
.	O
456	O

213579_s_at	O

E1A	B-GP
binding	I-GP
protein	I-GP
p300	I-GP

EP300	B-GP

22q13	O
.	O
2	O

-	O
0	O
.	O
742	O

-	O
0	O
.	O
404	O

*	O
Correlation	O
coefficient	O
(	O
r	O
)	O
of	O
probe	O
set	O
expression	O
with	O
MPRED	O
or	O
DEX	O
IC50	O
values	O
;	O
Chr	O
,	O
chromosomal	O
locus	O
;	O
bold	O
values	O
,	O
p	O
<	O
0	O
.	O
05	O
.	O

Genes	O
are	O
grouped	O
together	O
by	O
positive	O
(	O
top	O
)	O
or	O
negative	O
correlation	O
(	O
bottom	O
).	O

Reduced	O
MLL	B-GP
Expression	O
in	O
T	O
-	O
ALL	B-DS
Patients	O
is	O
Associated	O
with	O
GC	O
Resistance	O
and	O
Relapse	O

Since	O
our	O
data	O
indicated	O
an	O
association	O
between	O
GC	O
sensitivity	O
and	O
expression	O
levels	O
of	O
MLL	B-GP
in	O
T	O
-	O
ALL	B-DS
in	O
vitro	O
we	O
looked	O
for	O
further	O
evidence	O
in	O
the	O
literature	O
for	O
such	O
an	O
association	O
.	O

Holleman	O
et	O
al	O
previously	O
examined	O
the	O
ex	O
vivo	O
sensitivity	O
of	O
diagnostic	O
pediatric	O
ALL	B-DS
patient	O
specimens	O
to	O
individual	O
induction	O
therapy	O
agents	O
and	O
correlated	O
the	O
findings	O
with	O
gene	O
expression	O
data	O
measured	O
in	O
the	O
same	O
samples	O
using	O
HG	O
-	O
U133A	O
Affymetrix	O
microarrays	O
[	O
17	O
].	O

We	O
examined	O
this	O
data	O
for	O
the	O
expression	O
level	O
of	O
MLL	B-GP
in	O
T	O
-	O
ALL	B-DS
patient	O
specimens	O
from	O
this	O
cohort	O
that	O
were	O
determined	O
to	O
be	O
sensitive	O
or	O
resistant	O
to	O
prednisolone	O
.	O

Importantly	O
,	O
three	O
of	O
the	O
five	O
MLL	B-GP
probe	O
sets	O
on	O
the	O
array	O
showed	O
a	O
significantly	O
lower	O
expression	O
of	O
MLL	B-GP
in	O
resistant	O
samples	O
confirming	O
the	O
association	O
we	O
observed	O
in	O
T	O
-	O
ALL	B-DS
cell	O
lines	O
.	O

Figure	O
2A	O
shows	O
the	O
data	O
for	O
the	O
probe	O
set	O
with	O
the	O
strongest	O
association	O
(	O
212079_s_at	O
,	O
p	O
<	O
0	O
.	O
001	O
unpaired	O
t	O
-	O
test	O
),	O
and	O
for	O
the	O
summary	O
of	O
the	O
five	O
probe	O
sets	O
calculated	O
using	O
median	O
expression	O
values	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
unpaired	O
t	O
-	O
test	O
).	O

For	O
further	O
evidence	O
of	O
a	O
link	O
between	O
MLL	B-GP
expression	O
and	O
GC	O
resistance	O
we	O
examined	O
a	O
dataset	O
we	O
have	O
previously	O
published	O
comparing	O
gene	O
expression	O
patterns	O
in	O
pediatric	O
ALL	B-DS
specimens	O
taken	O
at	O
the	O
time	O
of	O
diagnosis	O
and	O
relapse	O
[	O
14	O
].	O

Although	O
we	O
were	O
not	O
able	O
to	O
directly	O
measure	O
the	O
GC	O
sensitivity	O
of	O
these	O
specimens	O
it	O
is	O
known	O
that	O
almost	O
all	O
patients	O
initially	O
respond	O
to	O
induction	O
therapy	O
and	O
achieve	O
first	O
remission	O
,	O
whilst	O
GC	O
resistance	O
is	O
a	O
well	O
-	O
documented	O
feature	O
of	O
relapse	O
[	O
25	O
,	O
26	O
].	O

It	O
is	O
therefore	O
reasonable	O
to	O
expect	O
that	O
many	O
of	O
the	O
relapse	O
specimens	O
in	O
this	O
cohort	O
would	O
have	O
elevated	O
GC	O
resistance	O
compared	O
to	O
their	O
diagnostic	O
counterparts	O
.	O

Examining	O
the	O
same	O
MLL	B-GP
probe	O
sets	O
as	O
above	O
,	O
we	O
observed	O
a	O
decrease	O
in	O
MLL	B-GP
expression	O
in	O
T	O
-	O
ALL	B-DS
relapse	O
specimens	O
vs	O
.	O
diagnosis	O
specimens	O
(	O
Figure	O
2B	O
)	O
comparable	O
to	O
that	O
measurable	O
in	O
GC	O
resistant	O
vs	O
.	O
sensitive	O
specimens	O
[	O
17	O
]	O
(	O
Figure	O
2A	O
).	O

This	O
differential	O
was	O
only	O
statistically	O
significant	O
for	O
probe	O
set	O
212079_s_at	O
(	O
p	O
<	O
0	O
.	O
001	O
,	O
unpaired	O
t	O
-	O
test	O
),	O
but	O
the	O
same	O
trend	O
was	O
visible	O
for	O
the	O
other	O
four	O
probe	O
sets	O
and	O
is	O
reflected	O
in	O
the	O
summary	O
of	O
the	O
median	O
expression	O
values	O
for	O
all	O
five	O
probes	O
(	O
Figure	O
2B	O
).	O

Since	O
both	O
of	O
these	O
studies	O
involve	O
T	O
-	O
ALL	B-DS
patients	O
it	O
is	O
likely	O
that	O
the	O
majority	O
of	O
patients	O
within	O
these	O
cohorts	O
do	O
not	O
have	O
rearrangements	O
affecting	O
MLL	B-GP
.	O

Taken	O
together	O
,	O
this	O
data	O
provides	O
clear	O
support	O
from	O
two	O
independent	O
data	O
sets	O
that	O
the	O
correlation	O
we	O
have	O
observed	O
between	O
wild	O
-	O
type	O
MLL	B-GP
expression	O
and	O
GC	O
sensitivity	O
in	O
T	O
-	O
ALL	B-DS
in	O
vitro	O
appears	O
to	O
also	O
be	O
relevant	O
in	O
vivo	O
.	O

Reduced	O
MLL	B-GP
expression	O
is	O
associated	O
with	O
GC	O
resistance	O
and	O
relapse	O
in	O
T	O
-	O
ALL	B-DS
patients	O
.	O

Published	O
HG	O
-	O
U133A	O
microarray	O
datasets	O
were	O
examined	O
for	O
the	O
expression	O
of	O
MLL	B-GP
using	O
either	O
a	O
single	O
probe	O
(	O
212079_s_at	O
)	O
or	O
the	O
median	O
of	O
all	O
five	O
MLL	B-GP
probe	O
sets	O
on	O
the	O
array	O
.	O

Data	O
represent	O
the	O
mean	O
±	O
SEM	O
(	O
linear	O
scale	O
)	O
of	O
the	O
indicated	O
patient	O
numbers	O
(	O
n	O
).	O

(	O
A	O
)	O
Difference	O
in	O
MLL	B-GP
expression	O
in	O
pediatric	O
T	O
-	O
ALL	B-DS
patient	O
specimens	O
with	O
ex	O
vivo	O
sensitivity	O
or	O
resistance	O
to	O
prednisolone	O
[	O
17	O
];	O
(	O
B	O
)	O
Difference	O
in	O
MLL	B-GP
expression	O
in	O
pediatric	O
T	O
-	O
ALL	B-DS
patient	O
specimens	O
measured	O
at	O
diagnosis	O
or	O
relapse	O
[	O
14	O
].	O

Relevance	O
of	O
MLL	B-GP
Expression	O
Level	O
in	O
Patients	O
with	O
MLL	B-GP
-	O
Disease	O

In	O
our	O
T	O
-	O
ALL	B-DS
cell	O
lines	O
we	O
observed	O
a	O
35	O
-	O
fold	O
variation	O
in	O
MLL	B-GP
expression	O
across	O
the	O
panel	O
that	O
correlated	O
with	O
GC	O
resistance	O
(	O
Figure	O
1A	O
).	O

To	O
assess	O
the	O
degree	O
with	O
which	O
endogenous	O
MLL	B-GP
expression	O
levels	O
vary	O
in	O
primary	O
ALL	B-DS
patient	O
specimens	O
we	O
analyzed	O
data	O
published	O
by	O
Ross	O
et	O
al	O
who	O
performed	O
gene	O
expression	O
profiling	O
of	O
pediatric	O
ALL	B-DS
subtypes	O
[	O
18	O
].	O

Figure	O
3A	O
shows	O
that	O
of	O
all	O
the	O
pediatric	O
ALL	B-DS
subtypes	O
,	O
the	O
widest	O
variations	O
in	O
MLL	B-GP
expression	O
levels	O
are	O
found	O
in	O
patients	O
with	O
T	O
-	O
lineage	O
ALL	B-DS
and	O
those	O
with	O
MLL	B-GP
-	O
rearrangements	O
.	O

To	O
examine	O
the	O
prognostic	O
relevance	O
of	O
MLL	B-GP
expression	O
variation	O
in	O
patients	O
with	O
MLL	B-GP
-	O
disease	O
we	O
examined	O
a	O
publication	O
describing	O
the	O
use	O
of	O
Affymetrix	O
HG	O
-	O
U95v2	O
microarrays	O
to	O
examine	O
gene	O
expression	O
patterns	O
in	O
ALL	B-DS
patients	O
with	O
MLL	B-GP
-	O
rearrangements	O
[	O
16	O
].	O

These	O
authors	O
reported	O
that	O
such	O
patients	O
could	O
be	O
clustered	O
on	O
the	O
basis	O
of	O
their	O
genome	O
-	O
wide	O
transcriptional	O
profile	O
into	O
two	O
distinct	O
subgroups	O
(	O
called	O
A	O
and	O
B	O
)	O
that	O
demonstrated	O
dramatically	O
different	O
survival	O
rates	O
(	O
Figure	O
3B	O
,	O
box	O
,	O
p	O
=	O
0	O
.	O
0005	O
).	O

By	O
analyzing	O
the	O
data	O
from	O
their	O
study	O
we	O
have	O
ascertained	O
that	O
the	O
expression	O
of	O
MLL	B-GP
was	O
significantly	O
lower	O
in	O
poor	O
-	O
outcome	O
patients	O
(	O
Group	O
A	O
)	O
compared	O
to	O
those	O
with	O
good	O
outcome	O
(	O
Figure	O
3B	O
,	O
bar	O
chart	O
,	O
p	O
=	O
0	O
.	O
008	O
).	O

The	O
HG	O
-	O
U95v2	O
probe	O
for	O
MLL	B-GP
targets	O
the	O
3	O
'	O
UTR	O
of	O
the	O
gene	O
,	O
meaning	O
that	O
it	O
would	O
either	O
detect	O
expression	O
of	O
the	O
full	O
-	O
length	O
(	O
non	O
-	O
translocated	O
)	O
MLL	B-GP
allele	O
remaining	O
in	O
these	O
patients	O
,	O
or	O
the	O
expression	O
of	O
any	O
reciprocal	O
fusion	O
that	O
was	O
transcribed	O
as	O
far	O
as	O
this	O
3	O
'	O
probe	O
.	O

Certainly	O
it	O
would	O
not	O
detect	O
signal	O
from	O
primary	O
MLL	B-GP
-	O
translocation	O
products	O
.	O

While	O
the	O
authors	O
did	O
not	O
experimentally	O
determine	O
GC	O
sensitivity	O
in	O
their	O
study	O
[	O
16	O
],	O
the	O
data	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
level	O
of	O
wild	O
-	O
type	O
MLL	B-GP
expression	O
is	O
linked	O
to	O
therapeutic	O
outcome	O
even	O
in	O
patients	O
that	O
have	O
an	O
MLL	B-GP
-	O
translocation	O
on	O
the	O
alternate	O
allele	O
.	O

MLL	B-GP
expression	O
patterns	O
in	O
patients	O
with	O
MLL	B-GP
-	O
disease	O
.	O

(	O
A	O
)	O
Box	O
and	O
whisker	O
plot	O
of	O
published	O
microarray	O
data	O
[	O
18	O
]	O
showing	O
the	O
variation	O
of	O
MLL	B-GP
expression	O
in	O
different	O
ALL	B-DS
subgroups	O
(	O
HG	O
-	O
U133Plus2	O
probe	O
212076_at	O
);	O
(	O
B	O
)	O
Analysis	O
of	O
published	O
microarray	O
data	O
from	O
ALL	B-DS
patients	O
with	O
MLL	B-GP
-	O
rearrangements	O
[	O
16	O
].	O

This	O
study	O
described	O
two	O
clusters	O
of	O
patients	O
(	O
A	O
and	O
B	O
)	O
with	O
significantly	O
different	O
survival	O
rates	O
(	O
boxed	O
data	O
)	O
and	O
expression	O
of	O
MLL	B-GP
(	O
graph	O
,	O
mean	O
±	O
SEM	O
).	O

MLL	B-GP
Knockdown	O
Increases	O
Resistance	O
to	O
GC	O
Exposure	O
and	O
DNA	O
Damage	O

To	O
assess	O
the	O
role	O
of	O
wild	O
-	O
type	O
MLL	B-GP
in	O
GC	O
resistance	O
phenotypes	O
we	O
used	O
a	O
retroviral	O
RNAi	O
expression	O
system	O
in	O
the	O
PER	O
-	O
117	O
T	O
-	O
ALL	B-DS
cell	O
line	O
to	O
generate	O
cell	O
lines	O
stably	O
expressing	O
shRNA	O
for	O
MLL	B-GP
(	O
MLL	B-GP
-	O
KD	O
)	O
or	O
a	O
non	O
-	O
silencing	O
shRNA	O
scrambled	O
control	O
(	O
MLL	B-GP
-	O
Scr	O
).	O
MLL	B-GP
mRNA	O
expression	O
in	O
MLL	B-GP
-	O
KD	O
cells	O
was	O
69	O
%	O
lower	O
on	O
average	O
than	O
in	O
MLL	B-GP
-	O
Scr	O
control	O
cells	O
as	O
assessed	O
by	O
qRT	O
-	O
PCR	O
(	O
Figure	O
4A	O
,	O
p	O
<	O
0	O
.	O
0001	O
).	O

This	O
correlated	O
to	O
a	O
~	O
20	O
%	O
reduction	O
in	O
MLL	B-GP
nuclear	O
protein	O
as	O
assessed	O
by	O
immunoblot	O
(	O
Figures	O
4B	O
and	O
4C	O
,	O
p	O
<	O
0	O
.	O
05	O
).	O

Proliferation	O
assays	O
demonstrated	O
that	O
MLL	B-GP
-	O
KD	O
cells	O
grew	O
approximately	O
10	O
%	O
faster	O
on	O
average	O
than	O
MLL	B-GP
-	O
Scr	O
cells	O
(	O
Figure	O
4D	O
,	O
p	O
<	O
0	O
.	O
05	O
ANOVA	O
).	O

To	O
assess	O
GC	O
sensitivity	O
in	O
the	O
two	O
lines	O
,	O
cell	O
viability	O
was	O
assessed	O
after	O
a	O
two	O
-	O
day	O
incubation	O
with	O
dexamethasone	O
(	O
Figure	O
4E	O
).	O

MLL	B-GP
-	O
KD	O
demonstrated	O
increased	O
viability	O
compared	O
to	O
MLL	B-GP
-	O
Scr	O
cells	O
at	O
all	O
doses	O
tested	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
two	O
-	O
way	O
ANOVA	O
)	O
indicating	O
GC	O
resistance	O
.	O

To	O
assess	O
the	O
specificity	O
of	O
this	O
protective	O
effect	O
we	O
examined	O
the	O
sensitivity	O
of	O
the	O
cells	O
to	O
gamma	O
-	O
irradiation	O
,	O
and	O
incubation	O
with	O
cytarabine	O
(	O
ARAC	O
)	O
and	O
methotrexate	O
(	O
MTX	O
).	O

Interestingly	O
,	O
MLL	B-GP
-	O
KD	O
cells	O
showed	O
greater	O
survival	O
following	O
gamma	O
-	O
irradiation	O
indicating	O
resistance	O
to	O
DNA	O
damage	O
(	O
Figure	O
5A	O
,	O
p	O
<	O
0	O
.	O
05	O
unpaired	O
t	O
-	O
test	O
).	O

Resistance	O
to	O
ARAC	O
and	O
MTX	O
however	O
was	O
not	O
significantly	O
different	O
between	O
the	O
two	O
cell	O
lines	O
.	O

The	O
proportion	O
of	O
dying	O
(	O
necrotic	O
)	O
cells	O
after	O
two	O
days	O
was	O
significantly	O
reduced	O
in	O
MLL	B-GP
-	O
KD	O
cells	O
in	O
response	O
to	O
both	O
dexamethasone	O
and	O
gamma	O
-	O
irradiation	O
,	O
indicating	O
a	O
cytoprotective	O
effect	O
of	O
MLL	B-GP
knockdown	O
(	O
Figure	O
5B	O
).	O

Baseline	O
viability	O
in	O
untreated	O
cells	O
was	O
not	O
significantly	O
different	O
between	O
the	O
cell	O
lines	O
.	O

Effect	O
of	O
MLL	B-GP
knockdown	O
on	O
proliferation	O
and	O
sensitivity	O
to	O
dexamethasone	O
.	O

(	O
A	O
)	O
Level	O
of	O
stable	O
MLL	B-GP
mRNA	O
knockdown	O
in	O
MLL	B-GP
-	O
KD	O
cells	O
as	O
measured	O
by	O
qRT	O
-	O
PCR	O
compared	O
to	O
MLL	B-GP
-	O
Scr	O
cells	O
expressing	O
non	O
-	O
silencing	O
scrambled	O
shRNA	O
;	O
(	O
B	O
)	O
Reduction	O
of	O
MLL	B-GP
nuclear	O
protein	O
expression	O
in	O
MLL	B-GP
-	O
KD	O
cells	O
as	O
assessed	O
by	O
immunoblot	O
detection	O
of	O
the	O
MLLC	O
proteolytic	O
fragment	O
from	O
four	O
independent	O
extractions	O
and	O
normalized	O
to	O
β	B-GP
-	I-GP
actin	I-GP
loading	O
control	O
;	O
(	O
C	O
)	O
Representative	O
immunoblot	O
of	O
nuclear	O
MLLC	O
(~	O
180	O
kD	O
,	O
top	O
panel	O
)	O
and	O
β	B-GP
-	I-GP
actin	I-GP
(	O
42	O
kD	O
,	O
bottom	O
panel	O
)	O
protein	O
expression	O
in	O
MLL	B-GP
-	O
Scr	O
and	O
MLL	B-GP
-	O
KD	O
cell	O
lines	O
;	O
(	O
D	O
)	O
Proliferation	O
of	O
MLL	B-GP
-	O
Scr	O
and	O
MLL	B-GP
-	O
KD	O
cell	O
lines	O
over	O
four	O
days	O
;	O
(	O
E	O
)	O
Differential	O
growth	O
of	O
MLL	B-GP
-	O
Scr	O
and	O
MLL	B-GP
-	O
KD	O
cells	O
over	O
two	O
days	O
in	O
the	O
presence	O
of	O
dexamethasone	O
;	O
In	O
each	O
case	O
(	O
A	O
-	O
B	O
,	O
D	O
-	O
E	O
)	O
data	O
represent	O
mean	O
±	O
SEM	O
from	O
3	O
-	O
6	O
independent	O
experiments	O
;	O
Statistical	O
analysis	O
was	O
by	O
t	O
-	O
test	O
(	O
A	O
,	O
B	O
)	O
or	O
ANOVA	O
(	O
D	O
,	O
E	O
);	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O

Effect	O
of	O
MLL	B-GP
knockdown	O
on	O
cellular	O
resistance	O
,	O
metabolism	O
and	O
GC	O
signaling	O
.	O

(	O
A	O
)	O
Effect	O
of	O
gamma	O
-	O
irradiation	O
(	O
γ	O
-	O
IR	O
,	O
1	O
Gy	O
),	O
methotrexate	O
(	O
MTX	O
,	O
0	O
.	O
01	O
μg	O
/	O
ml	O
),	O
cytarabine	O
(	O
ARAC	O
,	O
0	O
.	O
025	O
μg	O
/	O
ml	O
)	O
on	O
growth	O
of	O
MLL	B-GP
-	O
Scr	O
and	O
MLL	B-GP
-	O
KD	O
cell	O
lines	O
over	O
two	O
days	O
;	O
(	O
B	O
)	O
Percentage	O
of	O
dying	O
or	O
necrotic	O
cells	O
(	O
normalized	O
to	O
untreated	O
)	O
in	O
MLL	B-GP
-	O
Scr	O
and	O
MLL	B-GP
-	O
KD	O
after	O
48	O
hours	O
in	O
the	O
presence	O
of	O
dexamethasone	O
(	O
DEX	O
,	O
250	O
μM	O
or	O
500	O
μM	O
)	O
or	O
following	O
gamma	O
-	O
irradiation	O
(	O
γ	O
-	O
IR	O
,	O
1	O
Gy	O
);	O
(	O
C	O
)	O
Ratio	O
of	O
lactate	O
production	O
/	O
glucose	O
consumption	O
over	O
two	O
days	O
in	O
MLL	B-GP
-	O
Scr	O
and	O
MLL	B-GP
-	O
KD	O
cells	O
;	O
(	O
D	O
)	O
Relative	O
expression	O
of	O
GILZ	B-GP
mRNA	O
as	O
measured	O
by	O
qRT	O
-	O
PCR	O
in	O
MLL	B-GP
-	O
Scr	O
and	O
MLL	B-GP
-	O
KD	O
cell	O
lines	O
incubated	O
for	O
four	O
hours	O
in	O
the	O
absence	O
(-)	O
or	O
presence	O
(+)	O
of	O
dexamethasone	O
(	O
1	O
μM	O
);	O
In	O
each	O
case	O
(	O
A	O
-	O
D	O
)	O
data	O
represent	O
mean	O
±	O
SEM	O
from	O
3	O
-	O
6	O
independent	O
experiments	O
with	O
statistical	O
analysis	O
by	O
unpaired	O
t	O
-	O
test	O
;	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
01	O
.	O

To	O
assess	O
the	O
effects	O
of	O
MLL	B-GP
knockdown	O
on	O
cell	O
metabolism	O
we	O
compared	O
rates	O
of	O
glucose	O
consumption	O
and	O
lactate	O
production	O
between	O
the	O
two	O
cell	O
lines	O
.	O

Consistent	O
with	O
an	O
increased	O
rate	O
of	O
proliferation	O
MLL	B-GP
-	O
KD	O
cells	O
demonstrated	O
an	O
increased	O
rate	O
of	O
glucose	O
consumption	O
compared	O
to	O
control	O
cells	O
.	O

This	O
was	O
accompanied	O
by	O
a	O
decreased	O
rate	O
of	O
lactate	O
production	O
,	O
resulting	O
in	O
a	O
significant	O
drop	O
in	O
the	O
lactate	O
production	O
:	O
glucose	O
consumption	O
ratio	O
in	O
MLL	B-GP
-	O
KD	O
cells	O
(	O
Figure	O
5C	O
).	O

Finally	O
,	O
since	O
MLL	B-GP
is	O
known	O
to	O
be	O
a	O
master	O
transcriptional	O
regulator	O
we	O
assessed	O
whether	O
the	O
GC	O
resistant	O
phenotype	O
of	O
MLL	B-GP
-	O
KD	O
cells	O
might	O
represent	O
transcriptional	O
suppression	O
of	O
GC	O
response	O
elements	O
by	O
measuring	O
the	O
induction	O
of	O
GILZ	B-GP
,	O
a	O
well	O
-	O
characterized	O
GC	O
-	O
response	O
gene	O
,	O
following	O
incubation	O
with	O
dexamethasone	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
induction	O
of	O
GILZ	B-GP
mRNA	O
between	O
MLL	B-GP
-	O
KD	O
and	O
MLL	B-GP
-	O
Scr	O
cell	O
lines	O
following	O
a	O
4	O
hour	O
incubation	O
with	O
dexamethasone	O
(	O
Figure	O
5D	O
),	O
indicating	O
that	O
GC	O
-	O
transcriptional	O
responses	O
in	O
MLL	B-GP
-	O
KD	O
cells	O
appeared	O
to	O
be	O
intact	O
.	O

Discussion	O

Although	O
there	O
are	O
conflicting	O
reports	O
of	O
the	O
effect	O
of	O
MLL	B-GP
-	O
rearrangements	O
on	O
steroid	O
resistance	O
[	O
7	O
,	O
8	O
],	O
it	O
is	O
clear	O
that	O
all	O
infants	O
with	O
MLL	B-GP
-	O
rearrangements	O
have	O
significantly	O
worse	O
prognosis	O
than	O
those	O
with	O
non	O
-	O
rearranged	O
MLL	B-GP
regardless	O
of	O
the	O
type	O
of	O
translocation	O
involved	O
[	O
3	O
,	O
27	O
].	O

However	O
,	O
the	O
present	O
study	O
has	O
been	O
conducted	O
using	O
T	O
-	O
ALL	B-DS
cell	O
lines	O
without	O
MLL	B-GP
-	O
translocations	O
and	O
provides	O
evidence	O
that	O
in	O
the	O
absence	O
of	O
such	O
translocations	O
cellular	O
GC	O
sensitivity	O
is	O
related	O
to	O
the	O
level	O
of	O
expression	O
of	O
wild	O
-	O
type	O
MLL	B-GP
.	O

One	O
interpretation	O
of	O
this	O
data	O
is	O
that	O
alterations	O
in	O
MLL	B-GP
support	O
the	O
proliferative	O
phenotype	O
that	O
we	O
have	O
previously	O
associated	O
with	O
GC	O
resistance	O
[	O
11	O
].	O

In	O
lymphocytes	O
,	O
GCs	O
are	O
thought	O
to	O
trigger	O
a	O
metabolic	O
crisis	O
that	O
ultimately	O
leads	O
to	O
apoptosis	O
[	O
28	O
].	O

In	O
addition	O
to	O
suppressing	O
apoptotic	O
potential	O
through	O
the	O
modulation	O
of	O
mitochondrial	O
energetics	O
,	O
up	O
-	O
regulation	O
of	O
biosynthetic	O
and	O
metabolic	O
pathways	O
to	O
support	O
proliferation	O
may	O
therefore	O
confer	O
GC	O
resistance	O
by	O
offsetting	O
the	O
adverse	O
metabolic	O
consequences	O
of	O
GC	O
signalling	O
[	O
11	O
].	O
MLL	B-GP
has	O
recently	O
been	O
shown	O
to	O
be	O
important	O
for	O
the	O
control	O
of	O
cell	O
proliferation	O
but	O
the	O
mechanism	O
is	O
complex	O
,	O
involving	O
a	O
bimodal	O
pattern	O
of	O
expression	O
throughout	O
the	O
cell	O
cycle	O
[	O
29	O
].	O

In	O
our	O
experiments	O
,	O
suppression	O
of	O
MLL	B-GP
was	O
associated	O
with	O
a	O
small	O
increase	O
in	O
proliferation	O
and	O
glucose	O
consumption	O
but	O
decreased	O
lactate	O
production	O
,	O
indicating	O
a	O
shift	O
away	O
from	O
aerobic	O
glycolysis	O
to	O
alternative	O
pathways	O
,	O
such	O
as	O
oxidative	O
phosphorylation	O
or	O
the	O
pentose	O
-	O
phosphate	O
shunt	O
.	O

Besides	O
energy	O
production	O
,	O
these	O
pathways	O
are	O
essential	O
for	O
the	O
synthesis	O
of	O
macromolecules	O
,	O
nucleotides	O
and	O
nucleic	O
acids	O
required	O
for	O
proliferation	O
[	O
30	O
].	O

In	O
addition	O
to	O
elevated	O
GC	O
resistance	O
,	O
knockdown	O
of	O
MLL	B-GP
expression	O
was	O
associated	O
with	O
increased	O
resistance	O
to	O
gamma	O
-	O
irradiation	O
indicating	O
an	O
unexpected	O
protection	O
from	O
the	O
effects	O
of	O
DNA	O
-	O
damage	O
.	O

Recently	O
it	O
has	O
been	O
demonstrated	O
that	O
the	O
MLL	B-GP
family	O
of	O
H3K4	B-GP
methyltransferases	I-GP
are	O
critical	O
components	O
of	O
an	O
E2F1	B-GP
-	O
signalling	O
pathway	O
that	O
mediates	O
links	O
cell	O
cycle	O
control	O
to	O
DNA	O
damage	O
responses	O
,	O
and	O
that	O
their	O
knockdown	O
attenuates	O
the	O
apoptotic	O
response	O
to	O
adriamycin	O
[	O
31	O
].	O

This	O
highlights	O
the	O
tumor	B-DS
suppressor	O
role	O
of	O
these	O
proteins	O
and	O
is	O
consistent	O
with	O
the	O
protection	O
from	O
DNA	O
-	O
damage	O
we	O
have	O
observed	O
following	O
MLL	B-GP
-	O
knockdown	O
in	O
T	O
-	O
ALL	B-DS
cell	O
lines	O
.	O

In	O
contrast	O
however	O
,	O
no	O
protective	O
effect	O
of	O
MLL	B-GP
-	O
knockdown	O
was	O
seen	O
for	O
ARAC	O
or	O
MTX	O
in	O
the	O
present	O
study	O
.	O

Whilst	O
one	O
might	O
expect	O
that	O
suppression	O
of	O
DNA	O
-	O
damage	O
response	O
pathways	O
should	O
increase	O
resistance	O
to	O
both	O
of	O
these	O
agents	O
,	O
it	O
is	O
interesting	O
to	O
note	O
that	O
,	O
unlike	O
GCs	O
,	O
elevated	O
resistance	O
to	O
neither	O
of	O
these	O
drugs	O
is	O
associated	O
with	O
MLL	B-GP
-	O
rearrangement	O
[	O
32	O
,	O
33	O
];	O
infants	O
in	O
fact	O
are	O
known	O
to	O
be	O
generally	O
more	O
sensitive	O
to	O
ARAC	O
[	O
8	O
,	O
32	O
].	O

There	O
may	O
therefore	O
be	O
some	O
unexplained	O
insult	O
specificity	O
in	O
the	O
role	O
of	O
MLL	B-GP
in	O
mediating	O
responses	O
to	O
DNA	O
-	O
damage	O
.	O

Across	O
the	O
T	O
-	O
ALL	B-DS
cell	O
lines	O
there	O
was	O
a	O
35	O
-	O
fold	O
variation	O
in	O
the	O
level	O
of	O
MLL	B-GP
-	O
expression	O
.	O

Surprisingly	O
the	O
mechanisms	O
controlling	O
expression	O
of	O
wild	O
-	O
type	O
MLL	B-GP
have	O
not	O
been	O
extensively	O
studied	O
,	O
with	O
most	O
work	O
focusing	O
on	O
the	O
downstream	O
effects	O
of	O
the	O
gene	O
and	O
its	O
various	O
fusion	O
products	O
.	O

However	O
the	O
putative	O
MLL	B-GP
promoter	O
has	O
binding	O
motifs	O
for	O
a	O
large	O
number	O
of	O
transcription	O
factors	O
,	O
including	O
SREBF1	B-GP
(	O
sterol	B-GP
regulatory	I-GP
element	I-GP
binding	I-GP
transcription	I-GP
factor	I-GP
)	O
and	O
MYC	B-GP
.	O
MYC	B-GP
is	O
a	O
pivotal	O
player	O
in	O
the	O
control	O
of	O
cell	O
cycle	O
and	O
apoptosis	O
[	O
34	O
],	O
is	O
one	O
of	O
the	O
known	O
downstream	O
targets	O
of	O
GC	O
signaling	O
in	O
lymphocytes	O
[	O
35	O
],	O
and	O
has	O
been	O
reported	O
to	O
be	O
up	O
-	O
regulated	O
in	O
MLL	B-GP
-	O
disease	O
[	O
36	O
].	O
MLL	B-GP
expression	O
is	O
also	O
likely	O
to	O
be	O
subject	O
to	O
miRNA	O
control	O
,	O
with	O
numerous	O
miRNA	O
binding	O
sites	O
predicted	O
to	O
reside	O
in	O
the	O
MLL	B-GP
3	O
'	O
UTR	O
.	O

Although	O
downstream	O
effects	O
of	O
MLL	B-GP
or	O
MLL	B-GP
-	O
translocations	O
on	O
miRNA	O
expression	O
has	O
been	O
reported	O
by	O
a	O
number	O
of	O
groups	O
,	O
to	O
our	O
knowledge	O
only	O
one	O
recent	O
study	O
has	O
reported	O
the	O
upstream	O
miRNA	O
regulation	O
of	O
MLL	B-GP
itself	O
[	O
37	O
].	O

In	O
that	O
study	O
ectopic	O
expression	O
of	O
mirR	O
-	O
221	O
and	O
miR128	O
was	O
shown	O
to	O
affect	O
levels	O
of	O
MLL	B-GP
,	O
MLL	B-GP
-	O
fusions	O
and	O
GC	O
sensitivity	O
in	O
ALL	B-DS
cell	O
lines	O
[	O
37	O
],	O
consistent	O
with	O
the	O
hypothesis	O
that	O
levels	O
of	O
MLL	B-GP
expression	O
are	O
important	O
for	O
GC	O
resistance	O
.	O

It	O
remains	O
to	O
be	O
seen	O
whether	O
the	O
observed	O
effects	O
of	O
miRNA	O
ectopic	O
expression	O
on	O
GC	O
sensitivity	O
were	O
due	O
to	O
effects	O
on	O
MLL	B-GP
-	O
fusion	O
proteins	O
or	O
endogenous	O
wild	O
-	O
type	O
MLL	B-GP
and	O
the	O
hierarchy	O
for	O
these	O
mechanisms	O
therefore	O
remains	O
to	O
be	O
untangled	O
.	O

How	O
do	O
the	O
present	O
findings	O
,	O
performed	O
in	O
T	O
-	O
ALL	B-DS
with	O
no	O
MLL	B-GP
-	O
translocations	O
,	O
relate	O
to	O
patients	O
with	O
MLL	B-GP
-	O
disease	O
?	O

Although	O
loss	O
-	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
the	O
MLL	B-GP
locus	O
has	O
been	O
reported	O
to	O
be	O
a	O
relatively	O
frequent	O
event	O
in	O
childhood	O
ALL	B-DS
,	O
consistent	O
with	O
a	O
potential	O
role	O
as	O
a	O
tumor	B-DS
suppressor	O
[	O
38	O
],	O
this	O
is	O
not	O
the	O
case	O
in	O
patients	O
with	O
MLL	B-GP
-	O
disease	O
where	O
one	O
wild	O
-	O
type	O
copy	O
of	O
MLL	B-GP
appears	O
to	O
be	O
retained	O
[	O
38	O
-	O
40	O
].	O

This	O
indicates	O
that	O
allele	O
loss	O
and	O
MLL	B-GP
-	O
translocation	O
are	O
mutually	O
exclusive	O
oncogenic	O
events	O
,	O
but	O
little	O
focus	O
has	O
been	O
given	O
to	O
the	O
regulation	O
of	O
the	O
remaining	O
wild	O
-	O
type	O
allele	O
following	O
translocation	O
.	O

However	O
Whitman	O
et	O
al	O
have	O
recently	O
demonstrated	O
that	O
in	O
myeloid	B-DS
leukemia	I-DS
MLL	B-GP
partial	O
tandem	O
duplications	O
(	O
PTD	O
)	O
are	O
associated	O
with	O
silencing	O
of	O
the	O
wild	O
-	O
type	O
MLL	B-GP
copy	O
through	O
an	O
autoregulatory	O
mechanism	O
involving	O
altered	O
methylation	O
[	O
41	O
].	O

Interestingly	O
,	O
in	O
one	O
MLL	B-GP
-	O
PTD	O
patient	O
wild	O
-	O
type	O
MLL	B-GP
was	O
expressed	O
at	O
diagnosis	O
but	O
absent	O
at	O
relapse	O
,	O
suggesting	O
a	O
correlation	O
with	O
disease	O
progression	O
.	O

Wild	O
-	O
type	O
MLL	B-GP
expression	O
could	O
be	O
re	O
-	O
induced	O
in	O
primary	O
blasts	O
with	O
the	O
use	O
of	O
DNA	B-GP
methyltransferase	I-GP
(	O
DNMT	B-GP
)	O
or	O
histone	B-GP
deacetylase	I-GP
(	O
HDAC	B-GP
)	O
inhibitors	O
,	O
or	O
suppression	O
of	O
the	O
MLL	B-GP
-	O
PTD	O
transcript	O
,	O
and	O
was	O
associated	O
with	O
increased	O
apoptotic	O
sensitivity	O
and	O
reduced	O
colony	O
-	O
forming	O
capability	O
.	O

Other	O
workers	O
have	O
recently	O
demonstrated	O
down	O
-	O
regulation	O
of	O
wild	O
-	O
type	O
MLL	B-GP
in	O
myeloid	B-DS
leukemia	I-DS
patients	O
with	O
different	O
types	O
of	O
rearranged	O
-	O
MLL	B-GP
[	O
42	O
]	O
suggesting	O
that	O
it	O
may	O
be	O
a	O
common	O
feature	O
of	O
MLL	B-GP
-	O
related	O
leukemia	B-DS
.	O

Conclusions	O

Based	O
on	O
the	O
evidence	O
presented	O
we	O
hypothesize	O
that	O
GC	O
resistance	O
in	O
patients	O
with	O
MLL	B-GP
-	O
disease	O
may	O
partly	O
result	O
from	O
decreased	O
expression	O
and	O
tumor	B-DS
suppressive	O
effects	O
of	O
wild	O
-	O
type	O
MLL	B-GP
,	O
either	O
through	O
a	O
gene	O
-	O
dosage	O
effect	O
following	O
the	O
functional	O
loss	O
of	O
one	O
allele	O
via	O
translocation	O
,	O
auto	O
-	O
regulation	O
from	O
the	O
MLL	B-GP
-	O
fusion	O
protein	O
,	O
or	O
altered	O
miRNA	O
/	O
transcription	O
factor	O
signaling	O
.	O

This	O
would	O
help	O
to	O
explain	O
why	O
GC	O
-	O
resistance	O
is	O
a	O
common	O
feature	O
of	O
most	O
patients	O
with	O
MLL	B-GP
-	O
disease	O
despite	O
the	O
wide	O
variety	O
of	O
possible	O
gene	O
rearrangements	O
.	O

Amplifications	O
of	O
the	O
MLL	B-GP
gene	O
do	O
occur	O
but	O
are	O
much	O
more	O
rare	O
.	O

To	O
our	O
knowledge	O
only	O
one	O
report	O
exists	O
where	O
such	O
a	O
patient	O
has	O
been	O
tested	O
for	O
ex	O
vivo	O
GC	O
sensitivity	O
[	O
43	O
]	O
-	O
in	O
that	O
small	O
study	O
a	O
single	O
patient	O
with	O
MLL	B-GP
amplification	O
demonstrated	O
GC	O
sensitivity	O
whilst	O
all	O
patients	O
with	O
MLL	B-GP
deletions	O
or	O
rearrangements	O
demonstrated	O
GC	O
resistance	O
,	O
observations	O
entirely	O
consistent	O
with	O
our	O
hypothesis	O
.	O

We	O
do	O
not	O
propose	O
that	O
the	O
MLL	B-GP
-	O
translocation	O
event	O
itself	O
is	O
without	O
oncogenic	O
effects	O
since	O
this	O
has	O
been	O
clearly	O
demonstrated	O
by	O
other	O
workers	O
,	O
but	O
rather	O
that	O
our	O
data	O
may	O
help	O
to	O
explain	O
the	O
poor	O
-	O
response	O
to	O
therapy	O
in	O
this	O
disease	O
.	O

Neither	O
do	O
our	O
findings	O
negate	O
the	O
possibility	O
that	O
MLL	B-GP
-	O
fusion	O
proteins	O
themselves	O
may	O
have	O
additional	O
effects	O
upon	O
apoptotic	O
sensitivity	O
.	O

Indeed	O
,	O
recent	O
experiments	O
have	O
shown	O
that	O
multiple	O
MLL	B-GP
-	O
fusion	O
proteins	O
inhibit	O
p53	B-GP
and	O
confer	O
resistance	O
to	O
DNA	O
damage	O
[	O
44	O
].	O

However	O
,	O
it	O
is	O
important	O
to	O
note	O
that	O
in	O
these	O
experiments	O
fusion	O
protein	O
constructs	O
were	O
ectopically	O
expressed	O
into	O
cell	O
lines	O
containing	O
wild	O
-	O
type	O
MLL	B-GP
.	O

In	O
view	O
of	O
the	O
evidence	O
discussed	O
here	O
it	O
would	O
be	O
important	O
to	O
know	O
whether	O
expression	O
of	O
endogenous	O
MLL	B-GP
was	O
altered	O
during	O
these	O
experiments	O
and	O
whether	O
this	O
contributed	O
to	O
the	O
observed	O
anti	O
-	O
apoptotic	O
effects	O
.	O

Increased	O
resistance	O
to	O
DNA	O
damage	O
-	O
induced	O
apoptosis	O
has	O
been	O
proposed	O
as	O
a	O
phenotype	O
of	O
MLL	B-GP
-	O
disease	O
that	O
explains	O
the	O
short	O
latency	O
associated	O
with	O
disease	O
emergence	O
[	O
45	O
].	O

It	O
is	O
possible	O
that	O
this	O
effect	O
could	O
originate	O
from	O
the	O
loss	O
of	O
tumor	B-DS
suppressor	O
function	O
of	O
the	O
wild	O
-	O
type	O
MLL	B-GP
as	O
well	O
as	O
from	O
direct	O
anti	O
-	O
apoptotic	O
effects	O
of	O
the	O
fusion	O
protein	O
.	O

During	O
the	O
preparation	O
of	O
this	O
manuscript	O
Liu	O
et	O
al	O
[	O
46	O
]	O
published	O
a	O
report	O
describing	O
a	O
role	O
for	O
wild	O
-	O
type	O
MLL	B-GP
in	O
the	O
maintenance	O
of	O
genome	O
integrity	O
through	O
the	O
regulation	O
of	O
the	O
S	O
-	O
phase	O
cell	O
cycle	O
checkpoint	O
.	O

DNA	O
synthesis	O
in	O
cells	O
deficient	O
in	O
wild	O
-	O
type	O
MLL	B-GP
was	O
found	O
to	O
be	O
resistant	O
to	O
ionizing	O
radiation	O
and	O
a	O
range	O
of	O
DNA	O
-	O
damaging	O
agents	O
,	O
supporting	O
a	O
role	O
for	O
wild	O
-	O
type	O
MLL	B-GP
in	O
the	O
mediation	O
of	O
cellular	O
DNA	O
damage	O
responses	O
[	O
46	O
].	O

Under	O
this	O
model	O
,	O
MLL	B-GP
-	O
fusion	O
proteins	O
acted	O
as	O
dominant	O
negative	O
mutants	O
to	O
abrogate	O
the	O
ATR	B-GP
-	O
mediated	O
stabilization	O
of	O
wild	O
-	O
type	O
MLL	B-GP
reported	O
to	O
occur	O
in	O
response	O
to	O
DNA	O
damage	O
.	O

The	O
findings	O
are	O
in	O
keeping	O
with	O
those	O
from	O
the	O
present	O
study	O
and	O
support	O
our	O
conclusion	O
that	O
reduced	O
levels	O
of	O
wild	O
-	O
type	O
MLL	B-GP
can	O
contribute	O
to	O
increased	O
cellular	O
resistance	O
even	O
in	O
the	O
absence	O
of	O
an	O
MLL	B-GP
-	O
translocation	O
event	O
.	O

Conflicts	O
of	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

AHB	O
directed	O
research	O
,	O
analyzed	O
data	O
,	O
prepared	O
manuscript	O
;	O
JLR	O
,	O
MLP	O
,	O
JYSH	O
,	O
ALS	O
,	O
JF	O
performed	O
research	O
,	O
collected	O
and	O
analyzed	O
data	O
;	O
MJF	O
performed	O
bioinformatics	O
and	O
statistical	O
analysis	O
;	O
URK	O
designed	O
study	O
,	O
directed	O
research	O
,	O
revised	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

